COVID-19 booster discussions have led to a 'communications crisis' and 'nonstop' phone calls

The back-and-forth on COVID-19 booster shots among the Food and Drug Administration, the Centers for Disease Control and Prevention, and their advisory panels amounts to a "communications crisis," Robert Murphy, the executive director of the Institute for Global Health at Northwestern University Feinberg School of Medicine, told The Washington Post.
Many Americans seem like they aren't sure if they're eligible for a third dose of the Pfizer-BioNTech vaccine (the only one of the three available shots that's received formal discussions on boosters) because of hard-to-follow guidance from public health officials — first, the CDC advisory panel narrowed the FDA panel's initial recommendation, and then CDC Director Rochelle Walensky overruled that, broadening it again.
The situation, though, has led to a deluge of phone calls to healthcare providers at the local level. For instance, a customer service representative for Primary Health clinics in southwestern Idaho told the Post "the calls seem pretty nonstop." David Peterman, Primary Health's chief executive, said in light of the booster confusion "we went from 40,000 phone calls daily to 80,000," prompting him to ask staffers to take extra shifts.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Jay A. Winsten, the founding director of the Center for Health Communications at the Harvard T.H. Chan School of Public Health, thinks the solution should come from the top. While the FDA and CDC have a lot of experts in the health and science fields, "what's missing from the equation are communication experts," Winsten said, adding that "they need a seat at the table." Read more at The Washington Post.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
How to figure out when your tax refund will arrive
The explainer How long do you have to wait between submitting your return and receiving the money?
By Becca Stanek, The Week US Published
-
'It also means the start of a virtuous ecological cycle'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
Canada beats US in charged 4 Nations hockey final
Speed Read 'You can't take our country — and you can't take our game,' Prime Minister Justin Trudeau posted after the game
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published